FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2947996435> ?p ?o ?g. }

• W2947996435 endingPage "e15679" @default.
• W2947996435 startingPage "e15679" @default.
• W2947996435 abstract "e15679 Background: Molecular profiling has defined actionable mutations in HCC, and has the potential to be used for selection of targeted therapies, as well as for the characterization of predictive biomarkers from approved treatments. Noninvasive strategies are critical to HCC given the challenge of obtaining liver biopsies. We investigated whether profiling by ctDNA could provide predictive and/or prognostic information for HCC patients (pt) treated with immune checkpoint inhibitors. Methods: We analyzed blood samples from 22 HCC pt who underwent treatment with anti-PD-1 using comprehensive genomic testing of ctDNA with a commercially-available platform (Guardant Health, CA). Demographic and treatment data were retrospectively collected with the goal of correlating treatment outcomes and drug response (by imaging and/or AFP) with molecular abnormalities. Results: 17/22 (77.3%) were men; median age was 66 years. 21 patients received nivolumab and 1 received pembrolizumab. 9 were HCV positive and 5 were HBV positive. 15/22 patients had > 1 alteration identified. The median number of alterations/pt was 3 (range, 1-8). TP53 was the common altered gene (n = 11) followed by CTNBB1 (n = 8) , TERT (n = 5) KRAS (n = 3) , GNAS (n = 2). Mutations were also seen (n = 1) in KIT, PIK3CA, PTEN, EGFR, NTRK, FGFR2 among others. 6 pt (27.3%) had AFP response and 8 (36.4%) achieved disease control > 12 weeks. Mutations involving KIT, PIK3CA and PTEN were associated with shorter progression-free (PFS) (p < .001 for all) and overall survival (OS) (p = .028 for all), whereas GNAS mutation was associated with shorter PFS (p = 0.019) but not OS. No differences in OS or PFS was observed for other alterations, including the presence of CTNNB1 mutation. There were no correlations between specific alterations and objective tumor response (either by imaging or AFP). 32% of pt were progression-free at 6 months. Median OS was not reached, and 62% were alive after 1 year. Conclusions: Identifying non-invasive predictive biomarkers of benefit to immunotherapy is a priority in HCC. Our data suggest that specific ctDNA alterations can provide predictive information for survival (OS and PFS) on immune checkpoint inhibitors. Further larger studies are warranted for confirmation." @default.
• W2947996435 created "2019-06-07" @default.
• W2947996435 creator A5001295453 @default.
• W2947996435 creator A5001666207 @default.
• W2947996435 creator A5026480682 @default.
• W2947996435 creator A5032970786 @default.
• W2947996435 creator A5035371911 @default.
• W2947996435 creator A5041102881 @default.
• W2947996435 creator A5043534982 @default.
• W2947996435 creator A5046065062 @default.
• W2947996435 creator A5046213456 @default.
• W2947996435 creator A5049876808 @default.
• W2947996435 creator A5052650853 @default.
• W2947996435 creator A5052694396 @default.
• W2947996435 creator A5067227071 @default.
• W2947996435 creator A5076426660 @default.
• W2947996435 creator A5088389768 @default.
• W2947996435 date "2019-05-20" @default.
• W2947996435 modified "2023-10-14" @default.
• W2947996435 title "Molecular profiling by circulating tumor DNA (ctDNA) and benefit from anti-PD-1 in HCC." @default.
• W2947996435 doi "https://doi.org/10.1200/jco.2019.37.15_suppl.e15679" @default.
• W2947996435 hasPublicationYear "2019" @default.
• W2947996435 type Work @default.
• W2947996435 sameAs 2947996435 @default.
• W2947996435 citedByCount "1" @default.
• W2947996435 countsByYear W29479964352022 @default.
• W2947996435 crossrefType "journal-article" @default.
• W2947996435 hasAuthorship W2947996435A5001295453 @default.
• W2947996435 hasAuthorship W2947996435A5001666207 @default.
• W2947996435 hasAuthorship W2947996435A5026480682 @default.
• W2947996435 hasAuthorship W2947996435A5032970786 @default.
• W2947996435 hasAuthorship W2947996435A5035371911 @default.
• W2947996435 hasAuthorship W2947996435A5041102881 @default.
• W2947996435 hasAuthorship W2947996435A5043534982 @default.
• W2947996435 hasAuthorship W2947996435A5046065062 @default.
• W2947996435 hasAuthorship W2947996435A5046213456 @default.
• W2947996435 hasAuthorship W2947996435A5049876808 @default.
• W2947996435 hasAuthorship W2947996435A5052650853 @default.
• W2947996435 hasAuthorship W2947996435A5052694396 @default.
• W2947996435 hasAuthorship W2947996435A5067227071 @default.
• W2947996435 hasAuthorship W2947996435A5076426660 @default.
• W2947996435 hasAuthorship W2947996435A5088389768 @default.
• W2947996435 hasConcept C104317684 @default.
• W2947996435 hasConcept C121608353 @default.
• W2947996435 hasConcept C126322002 @default.
• W2947996435 hasConcept C143998085 @default.
• W2947996435 hasConcept C185592680 @default.
• W2947996435 hasConcept C190283241 @default.
• W2947996435 hasConcept C2777609662 @default.
• W2947996435 hasConcept C2777701055 @default.
• W2947996435 hasConcept C2780030458 @default.
• W2947996435 hasConcept C2780057760 @default.
• W2947996435 hasConcept C2780265364 @default.
• W2947996435 hasConcept C2781187634 @default.
• W2947996435 hasConcept C526805850 @default.
• W2947996435 hasConcept C55493867 @default.
• W2947996435 hasConcept C71924100 @default.
• W2947996435 hasConcept C74231797 @default.
• W2947996435 hasConcept C86554907 @default.
• W2947996435 hasConcept C90924648 @default.
• W2947996435 hasConceptScore W2947996435C104317684 @default.
• W2947996435 hasConceptScore W2947996435C121608353 @default.
• W2947996435 hasConceptScore W2947996435C126322002 @default.
• W2947996435 hasConceptScore W2947996435C143998085 @default.
• W2947996435 hasConceptScore W2947996435C185592680 @default.
• W2947996435 hasConceptScore W2947996435C190283241 @default.
• W2947996435 hasConceptScore W2947996435C2777609662 @default.
• W2947996435 hasConceptScore W2947996435C2777701055 @default.
• W2947996435 hasConceptScore W2947996435C2780030458 @default.
• W2947996435 hasConceptScore W2947996435C2780057760 @default.
• W2947996435 hasConceptScore W2947996435C2780265364 @default.
• W2947996435 hasConceptScore W2947996435C2781187634 @default.
• W2947996435 hasConceptScore W2947996435C526805850 @default.
• W2947996435 hasConceptScore W2947996435C55493867 @default.
• W2947996435 hasConceptScore W2947996435C71924100 @default.
• W2947996435 hasConceptScore W2947996435C74231797 @default.
• W2947996435 hasConceptScore W2947996435C86554907 @default.
• W2947996435 hasConceptScore W2947996435C90924648 @default.
• W2947996435 hasIssue "15_suppl" @default.
• W2947996435 hasLocation W29479964351 @default.
• W2947996435 hasOpenAccess W2947996435 @default.
• W2947996435 hasPrimaryLocation W29479964351 @default.
• W2947996435 hasRelatedWork W2272044596 @default.
• W2947996435 hasRelatedWork W2532961791 @default.
• W2947996435 hasRelatedWork W2799716227 @default.
• W2947996435 hasRelatedWork W2900971926 @default.
• W2947996435 hasRelatedWork W3032782140 @default.
• W2947996435 hasRelatedWork W3094946786 @default.
• W2947996435 hasRelatedWork W4200529536 @default.
• W2947996435 hasRelatedWork W4307261665 @default.
• W2947996435 hasRelatedWork W4362592556 @default.
• W2947996435 hasRelatedWork W4385330227 @default.
• W2947996435 hasVolume "37" @default.
• W2947996435 isParatext "false" @default.
• W2947996435 isRetracted "false" @default.
• W2947996435 magId "2947996435" @default.
• W2947996435 workType "article" @default.